Pharmacological inhibition of Nrf2 has been shown to improve the sensitivity to chemotherapeutic agents in non-small cell lung carcinoma, A549 lung cancer, hepatoma and pancreatic cancer cell lines [21,22]. This evidence concerns the gene NFE2L2 and lung carcinoma.